MORRISVILLE, N.C.--(BUSINESS WIRE)--Clinipace Worldwide, a global digital contract research organization (dCRO), has appointed Eric B. Grossman, MD, as Vice President and Medical Director.
An eminent nephrologist with over 30 years of industry and clinical experience, Dr. Grossman brings almost two decades of experience designing and conducting clinical studies for FDA submission and top-tier journal publication. In addition to his work in nephrology, Dr. Grossman has conducted studies across a broad range of therapeutic areas including cardiovascular, diabetes, urology, women’s health and oncology. He is Board Certified in Internal Medicine and Nephrology.
“I am delighted to join this innovative dCRO, and look forward to leading the efforts to become the preeminent CRO in nephrology-related studies” said Dr. Grossman.
“We welcome Eric Grossman to our senior management team at an important juncture in our history, as we further expand our efforts in the nephrology field,” said Clinipace President and CEO Jeff Williams. “I am certain our clients will find his clinical leadership and research experience incredibly valuable in the full-service work we do for them.”
Prior to joining Clinipace in April 2017, Dr. Grossman was most recently a consultant to the pharmaceutical industry with Bexon Clinical Consulting. Before that, he held positions with Reata Pharmaceuticals, Keryx Biopharmaceuticals, the New York Organ Donor Network and Pfizer. Dr. Grossman received an MD from the University of Chicago Pritzker School of Medicine. He completed his residency at the Tufts-New England Medical Center and his nephrology fellowship at Harvard Medical School’s Brigham and Women’s Hospital in Boston.
Also in this therapeutic area, Clinipace has recently become a member of the American Society of Nephrology’s Kidney Health Initiative (KHI). Company representatives will be attending the Fifth Annual KHI Stakeholders Meeting in Washington, DC, on May 24-25.
About Clinipace Worldwide
Clinipace Worldwide, a digital contract research organization (dCRO), pioneered an innovative, technology-amplified CRO service model to serve the unique needs of venture-backed, mid-tier and strategic pharmaceutical, biotechnology and medical device firms. Powered by Clinipace’s proprietary TEMPO™ eClinical platform and a team of experts with extensive knowledge in therapeutic areas such as oncology, cardiovascular, and metabolic diseases, gastroenterology, infectious diseases, nephrology, immunology and vaccines, the company assists life science firms in successfully executing regulatory strategies, clinical development and post-approval research programs. To learn more, visit www.Clinipace.com.